natgillin/translations-raw huggingface dataset:
in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
v kombinaciji s sulfonilsečnino in metforminom, kadar ob dieti, telesni aktivnosti in pri dvojnemu zdravljenju s temi zdravili, glikemija ni ustrezno urejena; v kombinaciji z insulinom in metforminom ali brez njega, ko takšen režim zdravljenja sam, ob dieti in telesni aktivnosti, ne zadošča za ustrezno urejanje glikemije.
in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy.
v kombinaciji z zaviralcem aromataze pri postmenopavzalnih ženskah z metastatsko boleznijo, pozitivno glede hormonskih receptorjev, ki trenutno niso namenjene za kemoterapijo.
in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.
v kombinaciji z zaviralcem aromataze za zdravljenje bolnic v postmenopavzi z metastatsko obliko raka dojk s pozitivnimi hormonskimi receptorji, ki predhodno niso bile zdravljene s trastuzumabom.
In combination with anaesthesia and tumour resection further side effects may occur:
V kombinaciji z anestezijo in odstranitvijo tumorja se lahko pojavijo nadaljnji neželeni učinki:
In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
V kombinaciji z bortezomibom za zdravljenje napredovalega diseminiranega plazmocitoma pri bolnikih, ki so pred tem že prejeli najmanj eno vrsto predhodnega zdravljenja in so bodisi že imeli presaditev kostnega mozga ali pa niso primerni zanjo.
in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).
v kombinaciji s kapecitabinom za bolnike z napredovalo ali metastatsko boleznijo, ki je napredovala po predhodnem zdravljenju, ki je moralo vključevati antracikline in taksane ter zdravljenje s trastuzumabom v primeru metastaz (glejte poglavje 5.1).
In combination with capecitabine, for patients 60 years of age or more, a starting dose reduction of capecitabine to 75% is recommended (see capecitabine summary of product characteristics).
V kombinaciji s kapecitabinom se priporoča zmanjšanje začetnega odmerka kapecitabina pri bolnikih, starejših od 60 let, na 75 % (glejte povzetek glavnih značilnosti kapecitabina).
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m2 every three weeks, combined with capecitabine at 1250 mg/m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period.
V kombinaciji s kapecitabinom je priporočeni odmerek docetaksela 75 mg/m2 na tri tedne, kombiniran s kapecitabinom 1.250 mg/m2 dvakrat na dan (v 30 minutah po obroku) 2 tedna, čemur sledi 1- tedenski premor.
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m² every three weeks, combined with capecitabine at 1250 mg/m² twice daily (within 30 minutes after a meal) for 2 weeks followed by 1-week rest period.
V kombinaciji s kapecitabinom je priporočeni odmerek docetaksela 75 mg/m² na tri tedne, kombiniran s kapecitabinom 1.250 mg/m² dvakrat na dan (v 30 minutah po obroku) 2 tedna, čemur sledi 1-tedenski premor.
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin > 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
V ključni klinični študiji docetaksela v kombinaciji s cisplatinom in 5-fluorouracilom pri bolnikih z adenokarcinomom želodca so izključili bolnike z ALT in/ali AST > 1,5 x ULN ter hkrati alkalno fosfatazo > 2,5 x ULN in bilirubinom > 1 x ULN; pri teh bolnikih ni mogoče priporočiti zmanjšanja odmerka in docetaksela se ne sme uporabljati, če ni strogo indiciran.
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin > 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
V ključni klinični študiji docetaksela v kombinaciji s cisplatinom in 5-fluorouracilom pri bolnikih z adenokarcinomom želodca so izključili bolnike z ALT in/ali AST > 1,5 x ULN ter hkrati alkalno fosfatazo > 2.5 x ULN in bilirubinom > 1 x ULN; pri teh bolnikih ni mogoče priporočiti zmanjšanja odmerka in docetaksela se ne sme uporabljati, če ni strogo indiciran.
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin> 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
V ključni klinični študiji docetaksela v kombinaciji s cisplatinom in 5-fluorouracilom pri bolnikih z adenokarcinomom želodca so izključili bolnike z ALT in/ali AST > 1,5 * ULN ter hkrati alkalno fosfatazo > 2,5 * ULN in bilirubinom > 1 * ULN; pri teh bolnikih ni mogoče priporočiti zmanjšanja odmerka in docetaksela se ne sme uporabljati, če ni strogo indiciran.
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST > 1.5 × ULN associated with alkaline phosphatase > 2.5 × ULN, and bilirubin> 1 x UNL; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
V ključnem kliničnem preskušanju docetaksela v kombinaciji s cisplatinom in 5-fluorouracilom pri bolnikih z adenokarcinomom želodca so izključili bolnike z ALT in/ali AST > 1,5 × ZMRO ter hkrati alkalno fosfatazo > 2,5 × ZMRO in bilirubinom > 1 × ZMRO; pri teh bolnikih ni mogoče priporočiti zmanjšanja odmerka in docetaksel se ne sme uporabljati, če ni izrecno indiciran.
in combination with dexamethasone (an anti-inflammatory medicine), in adults whose disease has been treated at least once in the past; for the treatment of adults with previously untreated (newly diagnosed) multiple myeloma, who are not eligible for bone marrow transplant.
v kombinaciji z deksametazonom (protivnetnim zdravilom) za zdravljenje odraslih, ki so se v preteklosti zaradi te bolezni zdravili vsaj enkrat; za zdravljenje odraslih s predhodno nezdravljenim (novo odkritim) multiplim mielomom, pri katerih presaditve kostnega mozga ni možno izvesti.
in combination with diabetes medicines taken by mouth in combination with a type of diabetes medicines called GLP-1 receptor agonists that are given by injection.
v kombinaciji z zdravili proti sladkorni bolezni, ki se zaužijejo peroralno; v kombinaciji z vrsto zdravil proti sladkorni bolezni, imenovano agonist receptorjev glukagonu podobnega peptida 1 (GLP-1), ki se dajejo z injiciranjem.
in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
v kombinaciji z docetakselom (glejte poglavje 5.1) za zdravljenje bolnikov z lokalno napredovalo ali metastatsko obliko raka dojk po neuspešni citotoksični kemoterapiji.
in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
v kombinaciji z docetakselom (glejte poglavje 5.1) zdravljenje bolnikov z lokalno napredovalo ali metastatsko obliko raka dojk po neuspešni citotoksični kemoterapiji.
in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
v kombinaciji z docetakselom za zdravljenje tistih bolnikov, ki še niso prejemali kemoterapije za metastatsko bolezen;
In combination with docetaxel: an increased incidence of grade 3 or 4 treatment-related adverse reactions and treatment-related serious adverse reactions were observed in patients 60 years of age or more (see section 5.1).
V kombinaciji z docetakselom: pri bolnikih, starih 60 let ali več, so opazili večjo pogostnost z zdravljenjem povezanih neželenih učinkov stopnje 3 ali 4 ter z zdravljenjem povezanih resnih neželenih učinkov (glejte poglavje 5.1).
In combination with docetaxel: an increased incidence of grade 3 or 4 treatment-related adverse reactions and treatment-related serious adverse reactions were observed in patients 60 years of age or more (see section 5.1).
V kombinaciji z docetakselom; pri bolnikih, starejših od 60 let je bila opažena povečana pogostost pojavljanja z zdravljenjem povezanih neželenih učinkov stopnje 3 ali 4 in in z zdravljenjem povezanih resnih neželenih učinkov (glejte poglavje 5.1).
in combination with efavirenz
kombinaciji z efavirenzom
in combination with injections of a short- or rapid-acting insulin at mealtimes
v kombinaciji z injekcijami počasi- ali hitrodelujočega insulina med jedjo;
in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
v kombinaciji z insulinom (tj. trotirno kombinirano zdravljenje) kot dodatek k dieti in telesni vadbi za izboljšanje urejenosti glikemije pri bolnikih, pri katerih s stabilnim odmerkom insulina in samim metforminom urejenost glikemije ni zadostna.
in combination with insulin in patients whose blood glucose is not adequately controlled by insulin and metformin alone; in combination with a sulphonylurea in patients whose blood glucose is not adequately controlled with the highest possible doses of a combined metformin and sulphonylurea treatment.
v kombinaciji z insulinom pri bolnikih, pri katerih raven glukoze v krvi ni zadostno uravnana samo z insulinom in metforminom; v kombinaciji s sulfonilsečnino pri bolnikih, pri katerih raven glukoze v krvi ni zadostno uravnana z najvišjimi možnimi odmerki metformina in sulfonilsečnine pri kombiniranem zdravljenju.
in combination with irinotecan-based chemotherapy, in first-line in combination with FOLFOX, as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
v kombinaciji s kemoterapijo na osnovi irinotekana; kot primarno zdravljenje v kombinaciji s FOLFOX; kot samostojno zdravilo pri bolnikih, pri katerih zdravljenje z oksaliplatinom in zdravljenje na osnovi irinotekana ni bilo uspešno in pri bolnikih, ki ne prenašajo irinotekana.
In combination with Kyprolis, lenalidomide is administered as 25 mg orally on days 1–21 and dexamethasone is administered as 40 mg orally or intravenously on days 1, 8, 15, and 22 of the 28 day cycles.
Zdravilo Kyprolis je treba uporabljati v kombinaciji s 25 mg lenalidomida peroralno od 1. do 21. dne ciklusa in 40 mg deksametazona peroralno ali intravensko 1., 8., 15. in 22. dan 28-dnevnega ciklusa.
in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.
v kombinaciji z metforminom (tj. trotirno kombinirano zdravljenje) kot dodatek k dieti in telesni vadbi za izboljšanje urejenosti glikemije pri odraslih bolnikih (še posebej bolnikih s prekomerno telesno maso) z neustrezno urejeno sladkorno boleznijo pri zdravljenju z metforminom v največjem odmerku, ki ga prenašajo, in s pioglitazonom.
In combination with metformin in drug-naïve patients
V kombinaciji z metforminom pri predhodno nezdravljenih bolnikih
in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone;
v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče doseči zadovoljivega uravnavanj, ali s sulfonilsečnino (drugo vrsto zdravila za zdravljenje sladkorne bolezni), če metformin ni primeren, pri bolnikih, pri katerih zgolj s sulfonilsečnino ni mogoče doseči zadovoljivega uravnavanja;
in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone;
v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče doseči zadovoljivega uravnavanja ali s sulfonilsečnino (drugo vrsto zdravila za zdravljenje sladkorne bolezni), če metformin ni primeren, pri bolnikih, pri katerih zgolj s sulfonilsečnino ni mogoče doseči zadovoljivega uravnavanja;
in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
v kombinaciji z metforminom, kadar ob dieti, telesni aktivnosti in zdravljenju z metforminom glikemija ni ustrezno urejena;
in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated
v kombinaciji z metotreksatom ali samostojno pri bolnikih, ki ne prenašajo metotreksata ali pri katerih je metotreksat kontraindiciran.
in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.
v kombinaciji z metotreksatom ali samostojno pri bolnikih, ki ne prenašajo metotreksata ali pri katerih je metotreksat kontraindiciran.
in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter (see sections 4.4 and 5.1).
v kombinaciji z neoadjuvantno kemoterapijo, čemur sledi adjuvantno zdravljenje z zdravilom Herceptin, za lokalno napredovalo (tudi vnetno) bolezen ali tumorje > 2 cm v premeru (glejte poglavji 4.4 in 5.1).
In combination with oral glucose­lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4 and 5.1 for available data on the different combinations).
V kombinaciji s peroralnimi antidiabetiki in/ali z bazalnim insulinom, če ta zdravila skupaj z dieto in s telesno vadbo ne zagotavljajo ustrezne urejenosti sladkorne bolezni (za razpoložljive podatke o različnih kombinacijah glejte poglavji 4.4 in 5.1).
In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 for data with respect to different combinations).
V kombinaciji z drugimi zdravili, ki znižujejo raven glukoze, vključno z insulinom, kadar le-ti skupaj z dieto in telesno vadbo ne zagotavljajo zadostne glikemične urejenosti (glejte poglavje 5.1 za podatke v zvezi z različnimi kombinacijami).
in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products (see sections 4.4, 4.5 and 5.1 for available data on different combinations) in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.
v kombinaciji z drugimi antidiabetiki, vključno z insulinom, pri bolnikih, ki niso zadostno urejeni z metforminom in temi zdravili (glejte poglavja 4.4, 4.5 in 5.1 za razpoložljive podatke o različnih kombinacijah), pri bolnikih, ki že prejemajo kombinacijo dapagliflozina in metformina v ločenih tabletah.
in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.
v kombinaciji s paklitakselom za zdravljenje tistih bolnikov, ki še niso prejemali kemoterapije za metastatsko bolezen in za katere antraciklini niso primerni;
in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.
v kombinaciji s pioglitazonom (tj. trotirno kombinirano zdravljenje) kot dodatek k dieti in telesni vadbi pri odraslih bolnikih z neustrezno urejeno sladkorno boleznijo pri zdravljenju z metforminom v največjem odmerku, ki ga prenašajo, in s pioglitazonom.
in combination with radiation therapy for locally advanced disease, in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.
v kombinaciji z radioterapijo za lokalno napredovalo bolezen; v kombinaciji s kemoterapijo na osnovi platine za ponavljajočo se in/ali metastatsko bolezen.
In combination with rosuvastatin for 3 months, no adverse effects were observed in cynomolgous monkeys at exposures much higher than patients receiving 420 mg evolocumab once monthly.
Med 3-mesečno uporabo v kombinaciji z rosuvastatinom pri opicah cynomolgus niso opazili neželenih učinkov ob izpostavljenostih, veliko večjih kot so pri bolnikih, zdravljenih s 420 mg evolokumaba enkrat na mesec.
In combination with sulphonylurea, the risk of hypoglycaemia may be lowered by a reduction in the dose of sulphonylurea.
Če se zdravilo uporablja v kombinaciji s sulfonilsečnino, se tveganje za pojav hipoglikemije lahko zmanjša z zmanjšanjem odmerka sulfonilsečnine.
In combination with tadalafil (another PAH medicine)
V kombinaciji s tadalafilom (drugo zdravilo za PAH)
In combination with tadalafil sudden hearing loss.
V kombinaciji s tadalafilom nenadna izguba sluha.
in combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation. in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).
v kombinaciji z melfalanom in prednizolonom, pri bolnikih, pri katerih bolezni še nismo zdravili in pri njih kemoterapija v visokih odmerkih, pred presaditvijo krvotvornih matičnih celic ni mogoča v kombinaciji z deksametazonom ali z deksametazonom in talidomidom, pri bolnikih, pri katerih bolezni še nismo zdravili in pred kemoterapijo v visokih odmerkih in presaditvijo krvotvornih matičnih celic (uvajalno zdravljenje).
in combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation. in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).
v kombinaciji z melfalanom in prednizonom pri bolnikih, pri katerih bolezni še nismo zdravili in pri njih kemoterapija v velikih odmerkih pred presaditvijo krvotvornih matičnih celic ni mogoča; v kombinaciji z deksametazonom ali z deksametazonom in talidomidom pri bolnikih, pri katerih bolezni še nismo zdravili ter pred kemoterapijo v velikih odmerkih in presaditvijo krvotvornih matičnih celic (uvajalno zdravljenje);
in combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation. in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).
v kombinaciji z melfalanom in prednizonom, pri bolnikih, pri katerih bolezni še nismo zdravili in pri njih kemoterapija v velikih odmerkih, pred presaditvijo krvotvornih matičnih celic ni mogoča v kombinaciji z deksametazonom ali z deksametazonom in talidomidom, pri bolnikih, pri katerih bolezni še nismo zdravili in pred kemoterapijo v velikih odmerkih in presaditvijo krvotvornih matičnih celic (uvajalno zdravljenje).
in combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation. in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).
v kombinaciji z melfalanom in prednizonom, pri bolnikih, pri katerih bolezni še niso zdravili in pri njih kemoterapija v velikih odmerkih, pred presaditvijo krvotvornih matičnih celic ni primerna. v kombinaciji z deksametazonom ali z deksametazonom in talidomidom, pri bolnikih, pri katerih bolezni še nismo zdravili in pred kemoterapijo v velikih odmerkih in presaditvijo krvotvornih matičnih celic (uvajalno zdravljenje).
in combination with trastuzumab for advanced or metastatic cancer that does not respond to hormones (hormone receptor-negative disease), and which got worse when previously treated with a combination of trastuzumab and other cancer medicines (chemotherapy); in combination with an aromatase inhibitor (another type of cancer medicine) in women who have been through the menopause, when the cancer is metastatic and responds to hormones.
v kombinaciji s trastuzumabom za zdravljenje napredovalega ali metastatskega raka, ki se ne odziva na hormone (bolezen, ki je negativna glede hormonskih receptorjev) in se je med predhodnimi zdravljenji s kombinacijo trastuzumaba in drugih zdravil proti raku (kemoterapijo) poslabšal; v kombinaciji z zaviralcem aromataze (drugo vrsto zdravila proti raku) pri ženskah po menopavzi, kadar je rak metastatski in se odziva na hormone.
in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy (see section 5.1).
v kombinaciji s trastuzumabom za bolnike z metastatsko boleznijo, negativno glede hormonskih receptorjev, ki je napredovala med predhodnim/i zdravljenjem/zdravljenji s trastuzumabom v kombinaciji s kemoterapijo (glejte poglavje 5.1).
In combination with trastuzumab the recommended dose of docetaxel is 100 mg/m2 every three weeks, with trastuzumab administered weekly.
Za kombinacijo s trastuzumabom je priporočeni odmerek docetaksela 100 mg/m2 vsake 3 tedne, s tedensko aplikacijo trastuzumaba.
In combined data analysis of VIEW1 and VIEW2, Eylea demonstrated clinically meaningful changes from baseline in pre-specified secondary efficacy endpoint National Eye Institute Visual Function Questionnaire (NEI VFQ-25), without clinically meaningful differences to ranibizumab.
V analizi združenih podatkov iz študij VIEW1 in VIEW2 je pri zdravljenju z zdravilom Eylea prišlo do klinično značilnih sprememb vnaprej določenega sekundarnega cilja učinkovitosti po vprašalniku National Eye Institute Visual Function Questionnaire (NEI VFQ-25) glede na izhodiščne vrednosti, brez klinično pomembnih razlik v primerjavi z ranibizumabom.